Skip to main content

Table 1 Patient demographic data

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

 

Adjuvant therapy

 

Goserelin

Chemotherapy

Age (year)

40.8 ± 6.5

41.9 ± 5.7

Follow-up (month)

168

273

10-year survival rate

0.88

0.82

Life expectancy of patient population (months)

432 ± 23

401 ± 17

Life expectancy of reference population (months)

474 ± 1

467 ± 1

Life time lost (months)

42

66